Viatris inc.VTRS.US Overview
VTRS Overall Performance
VTRS AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
VTRS Key Information
VTRS Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
VTRS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
VTRS Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Price of VTRS
VTRS FAQ
When is VTRS's latest earnings report released?
The most recent financial report for Viatris inc. (VTRS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VTRS's short-term business performance and financial health. For the latest updates on VTRS's earnings releases, visit this page regularly.
What is the operating profit of VTRS?
According to the latest financial report, Viatris inc. (VTRS) reported an Operating Profit of 178.8M with an Operating Margin of 4.76% this period, representing a decline of 20.85% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is VTRS's revenue growth?
In the latest financial report, Viatris inc. (VTRS) announced revenue of 3.76B, with a Year-Over-Year growth rate of 0.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does VTRS have?
As of the end of the reporting period, Viatris inc. (VTRS) had total debt of 14.44B, with a debt ratio of 0.38. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does VTRS have?
At the end of the period, Viatris inc. (VTRS) held Total Cash and Cash Equivalents of 975.3M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does VTRS go with three margins increasing?
In the latest report, Viatris inc. (VTRS) did not achieve the “three margins increasing” benchmark, with a gross margin of 36.5%%, operating margin of 4.76%%, and net margin of -3.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VTRS's profit trajectory and future growth potential.
Is VTRS's EPS continuing to grow?
According to the past four quarterly reports, Viatris inc. (VTRS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of VTRS?
Viatris inc. (VTRS)'s Free Cash Flow (FCF) for the period is 658.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 12.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of VTRS?
The latest valuation data shows Viatris inc. (VTRS) has a Price-To-Earnings (PE) ratio of -3.16 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.